SUMMARYDespite recent advances in pharmacological treatment of psychiatric disorders, lithium salts remain frequently used, as they are effective and inexpensive alternatives, especially in the treatment of bipolar disorders. Their use is commonly associated with various endocrine disorders, mainly in thyroid and parathyroid function, and in mineral metabolism. This article aims at reviewing these potential endocrinopathies related to the use of lithium to make health care professionals aware and familiar with these possible complications when they follow up patients using this drug, and to make them able to monitor, identify and institute early and appropriate treatment. SUMÁRIOApesar dos recentes avanços farmacológicos no tratamento dos transtornos psiquiátricos, os sais de lítio permanecem como uma alternativa eficaz e de menor custo, sendo usados com frequência principalmente no tratamento dos transtornos bipolares. O seu uso é comumente relacionado com diversas alterações endocrinológicas, principalmente nas funções tiroidiana, paratiroidiana e do metabolismo iônico. Este artigo tem por objetivo fazer uma revisão dessas potenciais endocrinopatias relacionadas ao uso do lítio, para que, no seguimento de pacientes em uso dessa medicação, os profissionais de saúde estejam atentos e familiarizados com essas possíveis complicações, conseguindo identificar e instituir tratamento precocemente. Arq Bras Endocrinol Metab. 2012;56(3):153-8 Descritores Lítio; hipercalcemia; diabetes insipidus; bócio

W e would like to thank you for your comments and interest in our article. Undoubtedly, the findings of your study add more information to the topic, with potential for further discussion.According to our knowledge, studies on the use of free T4 (fT4) as a biomarker for therapeutic adjustment in patients using lithium is still an underexplored and innovative field of research with very conflicting results in literature research.Some studies do show a decrease in fT4 as described in your study (1). Others try to correlate this finding with a worsening in clinical response, showing greater severity of depression and more affective disorders related with a decreased fT4 level, but in an uncontrolled setting (2). In another study, a decrease in fT4 levels correlated with improvement in maniac symptoms (3).Some other studies rather correlate higher T3 and fT3 levels with an improvement in psychiatric symptoms, instead of fT4 (4), describing a greater fT3/fT4 ratio as a favorable outcome marker of lithium prophylactic efficacy in major depressive disorders, and conceiving T3 concentration as a necessary condition to optimal therapeutic response (5).On the other hand, a study in rats showed greater fT4/fT3 ratio following lithium administration, suggesting lithium would have a more pronounced effect in decreasing fT3 rather than fT4 (6). We also found an study in schizophrenic patients suggesting a possible inhibitory effect of lithium on peripheral conversion of fT4 to fT3 in susceptible patients showing an increased fT4 after lithium administration (7). Another study over a 12-month period with bipolar patients showed elevation in TSH, but no changes in fT4, fT3, T3 and T4 during lithium treatment whatsoever (8).All these studies with these variable and conflicting findings show the need of further investigation to better understanding the relation of lithium and thyroid status concerning its therapeutic action in psychiatric disorders.